Evaluate long-term safety, tolerability, and efficacy of subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20) in participants with generalized myasthenia gravis (gMG) enrolled in the ADAPT-SC+ open-label extension (OLE) study.
No takes yet. Share an insight, caveat, or question.
Howard et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: